EcoDrugPlus

Estrogen Receptor 2a

Ensembl ID : ENSCCRG00000006684
Gene Symbol: ESR2A
1 Cross references
197 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSCCRG00000021944
Gene Symbol: ESR2A
1 Cross references
197 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSCCRG00000057096
Gene Symbol: ESR2B
1 Cross references
205 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSCCRG00000009130
Gene Symbol: ESR2B
1 Cross references
204 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSCCRG00000024681
Gene Symbol: ESRRGA
1 Cross references
202 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSCCRG00000071452
Gene Symbol: ESRRGA
1 Cross references
202 Possible Orthologues:

Exportin 1

Ensembl ID : ENSCCRG00000002433
Gene Symbol: XPO1
1 Cross references
224 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSCCRG00000001135
Gene Symbol: FDPS
1 Cross references
265 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSCCRG00000001171
Gene Symbol: FDPS
1 Cross references
266 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSCCRG00000018900
Gene Symbol: FNTA
1 Cross references
219 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSCCRG00000056910
Gene Symbol: FNTA
1 Cross references
219 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSCCRG00000080879
Gene Symbol: FNTB
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).